Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.72 |
| ▸ | DRD3 | P35462 | 10/20 | 0.72 |
| ▸ | DRD2 | P14416 | 8/20 | 0.72 |
| ▸ | HTR2A | P28223 | 6/20 | 0.69 |
| ▸ | HTR1A | P08908 | 5/20 | 0.69 |
| ▸ | HTR2C | P28335 | 3/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.69 |
| ▸ | DRD4 | P21917 | 1/20 | 0.67 |
| ▸ | HRH1 | P35367 | 1/20 | 0.64 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31061220 | 0.88 | DRD3 (0.84) | DRD3DRD2HTR2AHTR1AHTR2C | |
| SCHEMBL4521840 | 0.87 | DRD4 (0.77) | DRD3DRD2HTR2AHTR1AHTR2C | |
| SCHEMBL7058045 | 0.85 | DRD2 (0.75) | HSD17B10DRD3DRD2HTR2AHTR1A | |
| SCHEMBL7369877 | 0.84 | DRD3 (0.77) | HSD17B10DRD3DRD2HTR2AHTR1A | |
| SCHEMBL4522741 | 0.84 | HTR1A (0.79) | DRD3DRD2HTR2AHTR1AHTR2C | |
| SCHEMBL11065784 | 0.83 | KCNH2 (0.62) | HSD17B10DRD3DRD2HTR2AHTR1A | |
| SCHEMBL8475402 | 0.83 | DRD3 (0.60) | HSD17B10DRD3DRD2HTR2AHTR1A | |
| SCHEMBL13711963 | 0.83 | HTR2A (0.80) | DRD3DRD2HTR2AHTR1AHTR2C | |
| SCHEMBL7132544 | 0.83 | DRD2 (0.74) | DRD3DRD2HTR2AHTR1AHTR2C | |
| SCHEMBL10720723 | 0.82 | HSD17B10 (0.68) | HSD17B10DRD2HTR2ADRD4HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2009-09-24 | — | — | US | claimed |
| EP-1836192-A2 | ARYL PIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | Universita' Degli Studi di Siena (IT) | 2007-09-26 | — | — | EP | claimed |
| WO-2006072608-A2 | ARYL PIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | UNIVERSITÁ DEGLI STUDI DI SIENA (IT) | 2006-07-13 | — | — | WO | claimed |
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2009-09-24 | — | — | US | disclosed |
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2009-09-24 | — | — | US | disclosed |
| EP-1836192-A2 | ARYL PIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | Universita' Degli Studi di Siena (IT) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006072608-A2 | ARYL PIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | UNIVERSITÁ DEGLI STUDI DI SIENA (IT) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | HTR2C, HTR2A, DRD2 | HSD17B10 2475/4885DRD3 10/4885DRD2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.